BSE Live
Jan 09, 10:51Prev. Close
907.60
Open Price
905.65
Bid Price (Qty.)
905.10 (14)
Offer Price (Qty.)
905.75 (10)
NSE Live
Jan 09, 10:51Prev. Close
907.55
Open Price
906.95
Bid Price (Qty.)
905.35 (3)
Offer Price (Qty.)
905.40 (62)
| Key Financial Ratios of Zydus Lifesciences (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 13.80 | 14.51 | 10.66 | 6.47 | 19.90 | |
| Diluted EPS (Rs.) | 13.80 | 14.51 | 10.66 | 6.47 | 19.90 | |
| Cash EPS (Rs.) | 17.99 | 18.01 | 13.51 | 8.91 | 22.06 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 109.96 | 83.68 | 75.64 | 64.63 | 61.29 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 109.96 | 83.68 | 75.64 | 64.63 | 61.29 | |
| Dividend / Share(Rs.) | 3.50 | 3.50 | 3.50 | 3.20 | 3.20 | |
| Revenue from Operations/Share (Rs.) | 61.99 | 58.96 | 56.74 | 31.55 | 68.67 | |
| PBDIT/Share (Rs.) | 22.19 | 21.38 | 18.11 | 8.83 | 26.87 | |
| PBIT/Share (Rs.) | 18.00 | 17.88 | 15.25 | 6.38 | 24.71 | |
| PBT/Share (Rs.) | 15.21 | 17.00 | 14.62 | 6.27 | 24.45 | |
| Net Profit/Share (Rs.) | 13.80 | 14.51 | 10.65 | 6.46 | 19.90 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 35.80 | 36.25 | 31.91 | 27.98 | 39.12 | |
| PBIT Margin (%) | 29.04 | 30.32 | 26.86 | 20.22 | 35.98 | |
| PBT Margin (%) | 24.54 | 28.84 | 25.76 | 19.87 | 35.60 | |
| Net Profit Margin (%) | 22.25 | 24.60 | 18.77 | 20.48 | 28.97 | |
| Return on Networth / Equity (%) | 12.54 | 17.33 | 14.08 | 10.00 | 32.46 | |
| Return on Capital Employed (%) | 14.07 | 16.85 | 11.63 | 8.23 | 29.10 | |
| Return on Assets (%) | 8.53 | 10.86 | 8.96 | 5.99 | 22.83 | |
| Total Debt/Equity (X) | 0.26 | 0.39 | 0.34 | 0.42 | 0.16 | |
| Asset Turnover Ratio (%) | 38.34 | 44.16 | 47.76 | 29.24 | 78.80 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.39 | 1.52 | 1.27 | 0.71 | 1.52 | |
| Quick Ratio (X) | 0.99 | 0.99 | 0.80 | 0.40 | 1.18 | |
| Inventory Turnover Ratio (X) | 4.55 | 4.10 | 4.40 | 3.46 | 10.70 | |
| Dividend Payout Ratio (NP) (%) | 50.71 | 24.11 | 0.00 | 49.49 | 28.13 | |
| Dividend Payout Ratio (CP) (%) | 38.90 | 19.43 | 0.00 | 35.88 | 25.38 | |
| Earnings Retention Ratio (%) | 49.29 | 75.89 | 0.00 | 50.51 | 71.87 | |
| Cash Earnings Retention Ratio (%) | 61.10 | 80.57 | 0.00 | 64.12 | 74.62 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 29,920.14 | 38,722.54 | 41,241.96 | 48,157.00 | 33,326.28 | |
| EV/Net Operating Revenue (X) | 4.71 | 6.41 | 7.10 | 14.91 | 4.74 | |
| EV/EBITDA (X) | 13.17 | 17.69 | 22.24 | 53.26 | 12.11 | |
| MarketCap/Net Operating Revenue (X) | 4.31 | 5.88 | 6.67 | 14.05 | 4.62 | |
| Retention Ratios (%) | 49.28 | 75.88 | 0.00 | 50.50 | 71.86 | |
| Price/BV (X) | 2.43 | 4.14 | 5.01 | 6.86 | 5.17 | |
| Price/Net Operating Revenue | 4.31 | 5.88 | 6.67 | 14.05 | 4.62 | |
| Earnings Yield | 0.05 | 0.04 | 0.03 | 0.01 | 0.06 |
24.12.2025
Zydus Life shares gain on partnership with Swiss biopharmaceutical company
24.12.2025
16.12.2025
12.12.2025
12.11.2025
Zydus Life Standalone September 2025 Net Sales at Rs 2,871.20 crore, up 9.56% Y-o-Y
07.11.2025
Zydus Life Consolidated September 2025 Net Sales at Rs 6,123.20 crore, up 16.92% Y-o-Y
10.09.2025
Zydus Life Standalone June 2025 Net Sales at Rs 2,588.30 crore, down 37.78% Y-o-Y
24.06.2025
Zydus Life Consolidated March 2025 Net Sales at Rs 6,527.90 crore, up 17.96% Y-o-Y
12.07.2023
Zydus Lifescience Q1 PAT seen up 58.6% YoY to Rs 839.1 cr: Nirmal Bang
08.07.2022
Zydus Lifesciences Q1 PAT may dip 10.6% YoY to Rs 505.2 cr: Prabhudas Lilladher
13.01.2022
Cadila Healthcare Q3 PAT seen up 3.2% YoY to Rs 544 cr: Prabhudas Lilladher
06.10.2021
Cadila Healthcare Q2 PAT seen up 19% YoY to Rs 563.3 cr: Prabhudas Lilladher